Azitra (AZTR) Stock Analysis & Winston Score

Azitra is a small biotechnology company that develops treatments for skin diseases using live bacteria. The idea is to put helpful microbes directly on the skin to fix problems caused by an imbalance of bacteria. Their main focus is on rare and common skin conditions like Netherton syndrome and atopic dermatitis (eczema), targeting patients who have few good treatment options today. Azitra makes money by advancing drug candidates through clinical trials, with the goal of eventually selling approved therapies or licensing them to larger pharmaceutical companies. The company is based in the United States and is very early-stage, meaning it has no product revenue yet and depends on grants and investor funding to operate. Its competitive angle is its proprietary platform for engineering skin bacteria as drug delivery tools, but the biggest risk is the long, expensive road through clinical trials — most early-stage biotech drugs never reach approval.